Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative
- PMID: 17785546
- DOI: 10.1158/1078-0432.CCR-07-1041
Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative
Abstract
Purpose: As an approach to evaluate the expression pattern and status of activation of signaling pathways in clinical specimens from head and neck squamous cell carcinoma (HNSCC) patients, we established the Head and Neck Cancer Tissue Array Initiative, an international consortium aimed at developing a high-density HNSCC tissue microarray, with a high representation of oral squamous cell carcinoma.
Experimental design: These tissue arrays were constructed by acquiring cylindrical biopsies from multiple individual tumor tissues and transferring them into tissue microarray blocks. From a total of 1,300 cases, 547 cores, including controls, were selected and used to build the array.
Results: Emerging information by the use of phosphospecific antibodies detecting the activated state of signaling molecules indicates that the Akt-mammalian target of rapamycin (mTOR) pathway is frequently activated in HNSCC, but independently from the activation of epidermal growth factor receptor or the detection of mutant p53. Indeed, we identified a large group of tissue samples displaying active Akt and mTOR in the absence of epidermal growth factor receptor activation. Furthermore, we have also identified a small subgroup of patients in which the mTOR pathway is activated but not Akt, suggesting the existence of an Akt-independent signaling route stimulating mTOR.
Conclusions: These findings provide important information about the nature of the dysregulated signaling networks in HNSCC and may also provide the rationale for the future development of novel mechanism-based therapies for HNSCC patients.
Similar articles
-
Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.Cancer Res. 2005 Nov 1;65(21):9953-61. doi: 10.1158/0008-5472.CAN-05-0921. Cancer Res. 2005. PMID: 16267020
-
Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.Clin Cancer Res. 2004 Sep 1;10(17):5820-7. doi: 10.1158/1078-0432.CCR-03-0483. Clin Cancer Res. 2004. PMID: 15355912
-
Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model.Cancer Prev Res (Phila). 2009 Jan;2(1):27-36. doi: 10.1158/1940-6207.CAPR-08-0147. Cancer Prev Res (Phila). 2009. PMID: 19139015
-
The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies.Oral Dis. 2015 Oct;21(7):815-25. doi: 10.1111/odi.12206. Epub 2013 Dec 23. Oral Dis. 2015. PMID: 24219320 Review.
-
Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.Curr Opin Oncol. 2008 May;20(3):256-63. doi: 10.1097/CCO.0b013e3282f9b575. Curr Opin Oncol. 2008. PMID: 18391623 Review.
Cited by
-
A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.Cancer. 2013 May 15;119(10):1823-31. doi: 10.1002/cncr.27986. Epub 2013 Feb 13. Cancer. 2013. PMID: 23408298 Free PMC article. Clinical Trial.
-
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention.Clin Cancer Res. 2012 Jul 1;18(13):3705-13. doi: 10.1158/1078-0432.CCR-11-3271. Epub 2012 May 10. Clin Cancer Res. 2012. PMID: 22577058 Free PMC article.
-
Development of ATP-competitive mTOR inhibitors.Methods Mol Biol. 2012;821:447-60. doi: 10.1007/978-1-61779-430-8_29. Methods Mol Biol. 2012. PMID: 22125084 Free PMC article.
-
Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas.Oncotarget. 2016 May 17;7(20):29780-93. doi: 10.18632/oncotarget.8957. Oncotarget. 2016. PMID: 27119232 Free PMC article.
-
Ribosomal proteins induce stem cell-like characteristics in glioma cells as an "extra-ribosomal function".Brain Tumor Pathol. 2022 Apr;39(2):51-56. doi: 10.1007/s10014-022-00434-5. Epub 2022 May 5. Brain Tumor Pathol. 2022. PMID: 35508789 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous